Joshua Isner Sells 1,291 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXON) President Joshua Isner sold 1,291 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $642.43, for a total transaction of $829,377.13. Following the completion of the sale, the president now directly owns 181,892 shares in the company, valued at approximately $116,852,877.56. The trade was a 0.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Joshua Isner also recently made the following trade(s):

• On Tuesday, November 12th, Joshua Isner sold 20,000 shares of Axon Enterprise stock. The stock was sold at an average price of $606.15, for a total value of $12,123,000.00.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $615.68 on Friday. The stock’s fifty day moving average price is $555.56 and its two-hundred day moving average price is $414.18. The firm has a market cap of $46.95 billion, a PE ratio of 159.09, a price-to-earnings-growth ratio of 14.19 and a beta of 1.01. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise, Inc. has a one year low of $241.72 and a one year high of $698.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Insigneo Advisory Services LLC grew its stake in Axon Enterprise by 1.4% during the third quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock worth $627,000 after buying an additional 22 shares in the last quarter. Menard Financial Group LLC increased its stake in Axon Enterprise by 0.8% in the third quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company’s stock valued at $1,204,000 after acquiring an additional 24 shares during the last quarter. PFG Investments LLC increased its stake in Axon Enterprise by 0.6% in the third quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock valued at $1,547,000 after acquiring an additional 25 shares during the last quarter. Gladstone Institutional Advisory LLC raised its position in Axon Enterprise by 1.6% during the third quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 26 shares in the last quarter. Finally, Mather Group LLC. boosted its holdings in shares of Axon Enterprise by 3.7% in the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 27 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Robert W. Baird lifted their target price on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. Northland Securities upped their price objective on shares of Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. The Goldman Sachs Group lifted their target price on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Finally, Needham & Company LLC increased their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus target price of $488.67.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.